+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast to 2030- Product Image
Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast to 2030- Product Image
Sale

Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5181418
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Healthcare-associated Infectious Disease Diagnostics Market is evolving rapidly, driven by advancements in technology, regulatory changes, and shifting healthcare priorities. Senior executives in diagnostics, hospital administration, and supply chain management require evidence-based insights to navigate this landscape and prioritize their investments accordingly.

Market Snapshot: Healthcare-associated Infectious Disease Diagnostics Market

The Healthcare-associated Infectious Disease Diagnostics Market grew from USD 4.37 billion in 2024 to USD 4.76 billion in 2025. It is expected to continue growing at a CAGR of 8.39%, reaching USD 7.10 billion by 2030. Growth is propelled by increasing focus on infection prevention in healthcare settings, urgent demand for faster detection of pathogens, and constant requirements to monitor antimicrobial resistance. These factors are prompting healthcare facilities to implement cutting-edge molecular and immunoassay solutions, supported by policy shifts and evolving reimbursement models.

Scope & Segmentation

This research defines the competitive and technological contours of the healthcare-associated infectious disease diagnostics space, mapping the following coverage areas for strategic evaluation:

  • Test Methods: Immunoassays (chemiluminescent immunoassays, ELISA, lateral flow assays), microbiology (aerobic and anaerobic culture, microscopy, sensitivity testing), molecular diagnostics (isothermal amplification, PCR, sequencing).
  • Pathogen Types: Bacterial (e.g., Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus), fungal (Aspergillus, Candida, Cryptococcus), parasitic (malaria parasites, Toxoplasma gondii), viral (coronavirus, influenza, norovirus, RSV).
  • End Users: Diagnostic laboratories (independent, reference), hospitals (clinical pathology, microbiology labs), point-of-care settings (clinics, emergency departments, long-term care).
  • Sample Types: Blood (serum, whole blood), cerebrospinal fluid, respiratory (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), wound swabs (deep tissue and surface samples).
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Key Players Assessed: Roche Diagnostics International AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Becton, Dickinson and Company, bioMérieux SA, QIAGEN N.V., Bio-Rad Laboratories, Inc., DiaSorin S.p.A.

Key Takeaways for Senior Decision Makers

  • Rapid molecular and sequencing technologies are shifting infection management from centralized labs to near-patient and decentralized environments, enabling quicker therapeutic decisions.
  • Integrated digital diagnostics are enhancing outbreak surveillance, supporting data-driven antimicrobial stewardship, and producing operational efficiencies across care settings.
  • Supply chain resilience and local manufacturing partnerships are increasingly prioritized due to regulatory and macroeconomic factors, ensuring continuity in diagnostics provision.
  • Global harmonization of regulatory approval is supporting faster market entry and innovation diffusion, yet local reimbursement complexity continues to shape commercial strategy.
  • Point-of-care diagnostics are expanding in clinics and long-term care, with sensitivity and ease-of-use essential to gain clinical adoption across diverse user profiles.
  • Segment diversity—from pathogens to sample types—requires organizations to align portfolios and go-to-market approaches according to end-user needs and local infrastructure conditions.

Tariff Impact: U.S. 2025 Adjustments

Revised U.S. tariffs in 2025 increased costs on imported reagents, consumables, and diagnostic components. This shift caused diagnostic developers and labs to review their sourcing strategies, often pursuing domestic manufacturing or alternative supply networks. Competitive dynamics favored established multinationals with existing local operations, while smaller innovators navigated tariff-exemption pathways or supply chain risk mitigation. Flexible procurement frameworks and resilience now weigh significantly in vendor evaluation and strategic planning.

Methodology & Data Sources

This report uses an integrated approach including interviews with industry leaders, laboratory directors, and clinicians; review of peer-reviewed literature; regulatory filings; patent analysis; and assessment of publicly available company information. Extensive validation ensures findings reflect current market conditions and stakeholder priorities.

Why This Report Matters

  • Enables senior leaders to evaluate shifting regulatory, technological, and supply chain dynamics with a focus on actionable strategic priorities.
  • Delivers granular segmentation and regional analysis supporting targeted investment and product development in both mature and emerging healthcare markets.
  • Helps organizations benchmark their position against global competitors and identify opportunities for innovation and partnership.

Conclusion

This research provides a strategic, data-driven foundation for advancing diagnostics leadership amid changing healthcare and regulatory dynamics. The actionable insights presented support resilient growth, improved operational efficiency, and enhanced patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method
8.1. Introduction
8.2. Immunoassays
8.2.1. Chemiluminescent Immunoassay
8.2.2. ELISA
8.2.3. Lateral Flow Assays
8.3. Microbiology
8.3.1. Culture
8.3.1.1. Aerobic Culture
8.3.1.2. Anaerobic Culture
8.3.2. Microscopy
8.3.3. Sensitivity Testing
8.4. Molecular Diagnostics
8.4.1. Isothermal Amplification
8.4.2. PCR
8.4.3. Sequencing
9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type
9.1. Introduction
9.2. Bacterial
9.2.1. Clostridium Difficile
9.2.2. Escherichia Coli
9.2.3. Pseudomonas Aeruginosa
9.2.4. Staphylococcus Aureus
9.3. Fungal
9.3.1. Aspergillus Species
9.3.2. Candida Species
9.3.3. Cryptococcus Neoformans
9.4. Parasitic
9.4.1. Malaria Parasites
9.4.2. Toxoplasma Gondii
9.5. Viral
9.5.1. Coronavirus
9.5.2. Influenza Virus
9.5.3. Norovirus
9.5.4. Respiratory Syncytial Virus
10. Healthcare-associated Infectious Disease Diagnostics Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.2.1. Independent Laboratories
10.2.2. Reference Laboratories
10.3. Hospitals
10.3.1. Clinical Pathology Laboratories
10.3.2. Microbiology Laboratories
10.4. Point of Care
10.4.1. Clinics
10.4.2. Emergency Departments
10.4.3. Long Term Care Facilities
11. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type
11.1. Introduction
11.2. Blood
11.2.1. Serum
11.2.2. Whole Blood
11.3. Cerebrospinal Fluid
11.4. Respiratory
11.4.1. Bronchoalveolar Lavage
11.4.2. Nasopharyngeal Swabs
11.4.3. Sputum
11.5. Urine
11.5.1. Catheterized Urine
11.5.2. Midstream Urine
11.6. Wound Swabs
11.6.1. Deep Tissue Samples
11.6.2. Surface Swabs
12. Americas Healthcare-associated Infectious Disease Diagnostics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Diagnostics International AG
15.3.2. Abbott Laboratories
15.3.3. Danaher Corporation
15.3.4. Thermo Fisher Scientific Inc.
15.3.5. Siemens Healthineers AG
15.3.6. Becton, Dickinson and Company
15.3.7. bioMérieux SA
15.3.8. QIAGEN N.V.
15.3.9. Bio-Rad Laboratories, Inc.
15.3.10. DiaSorin S.p.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 120. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 121. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 122. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 123. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 124. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 125. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 126. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 127. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 128. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 129. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 130. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 132. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 134. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 135. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 136. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 137. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 138. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 140. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 145. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 146. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 147. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 148. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 149. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 154. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 155. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 156. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 157. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 235. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 236. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 238. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 239. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 240. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 241. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 242. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 243. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 244. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 245. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 247. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 249. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 250. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 251. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 252. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 253. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 254. FRANCE HEALTH

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Healthcare-associated Infectious Disease Diagnostics market report include:
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • bioMérieux SA
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.1 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Infectious Diseases in-Vitro Diagnostics Market by Test Type, Technology, Pathogen, End User, Application - Global Forecast to 2030 - Product Image

Infectious Diseases in-Vitro Diagnostics Market by Test Type, Technology, Pathogen, End User, Application - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Sexually Transmitted Disease Diagnostics Market by Diagnostic Test Types, Pathogen Types, End-User Types, Sample Types, Technology Types, Product Types - Global Forecast to 2030 - Product Image

Sexually Transmitted Disease Diagnostics Market by Diagnostic Test Types, Pathogen Types, End-User Types, Sample Types, Technology Types, Product Types - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Gastrointestinal Pathogen Testing Market Report 2025 - Product Image

Gastrointestinal Pathogen Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hospital Acquired Infections Testing Kits Market Report 2025 - Product Image

Hospital Acquired Infections Testing Kits Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Hospital Acquired Infection Diagnostics Market

The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics. The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection. Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.